

N THE UNITED STATES PATENT AND TRADEMARK OFFICE

= 714

In re application of: Baichwal et al.

Serial No. 09/758,003

Filed: January 9, 2001

Title: RIP: Novel Human Protein Involved in Tumor Necrosis Factor Signal Transduction Group Art Unit: 1645

Examiner: Not yet assigned

Attorney Docket No. T95-006-2

THE REPORTION

CERTIFICATE OF MAILING

Thereby certify that this corr. is being deposited with the US Postal Service as First Class Mail in an envelope addressed to the Comm. for Patents, Washington, D.C. 20231 on November 14, 2001

Signed ////

Richard Osman

SUBMISSION OF DEFICIENCY PAYMENT UNDER 37CFR1.28(c)

The Commissioner for Patents Washington, DC 20231

Dear Commissioner:

The fees in this application were paid in good faith as a small entity. I have since discovered, however, that the fees should have been paid as a large entity, thus through an error, the Office was not previously notified of this change in entity status. Accordingly, enclosed is our check for \$475.00 representing the deficiency owed for these fees as a large entity.

Itemization of Deficiency Payment:

(A) Type of fee:

1) Filing fee; Current fee amount for non-small entity: \$740.00.

2) Excess claims fee (10 claims); Current fee amount for non-small entity: \$180.00.

(B) Small entity fee paid:

1) \$355.00 on January 9, 2001

2) \$90.00 on January 9, 2001

(C) Deficiency owed:

1) \$385.00

2) \$90.00

(where a fee paid in error as a small entity was subject to a fee decrease between the time the fee was paid in error and the time the deficiency is paid in full, the deficiency owed is equal to the amount previously paid in error)

(D) Total deficiency payment: \$475.00.

The Commissioner is hereby authorized to charge any fees or credit any overcharges, if necessary, relating to this communication to our Deposit Account No. 19-0750 (order no. T95-006-2).

Respectfully submitted,

SCIENCE & TECHNOLOGY LAW GROUP

Richard Aron Osman, Ph.D., Reg. No. 36.627

Tel: (650) 343-4341; Fax: (650)343-4342